Category: Advantages of Conducting Trials in Latin America

Introduction

In the rapidly evolving landscape of clinical research, innovative trial designs are reshaping how therapies are developed and evaluated, particularly in regions like Argentina.

• Adaptive trial designs
• Platform trials
• Basket trials

These methodologies are at the forefront, offering unprecedented flexibility and efficiency in testing new treatments. These methodologies not only optimize patient outcomes but also significantly reduce costs, making them appealing to Medtech companies. As the demand for patient-centric approaches and real-world evidence grows, researchers are increasingly turning to digital health technologies and strategic partnerships with local CROs to streamline operations and enhance recruitment.

This article delves into the transformative impact of these trial designs and methodologies, highlighting their potential to revolutionize clinical research and improve patient care in Argentina and beyond.

Adaptive Trial Designs

are increasingly recognized in clinical research for their inherent flexibility, enabling real-time adjustments to protocols based on emerging data. This adaptability empowers researchers to modify sample sizes, treatment regimens, or endpoints as the study unfolds. For instance, if initial findings reveal a treatment’s exceptional efficacy, the study can be recalibrated to allocate a larger number of participants to that treatment group, thereby enhancing outcomes for individuals. This methodology not only boosts testing efficiency but also significantly reduces expenses by minimizing unnecessary patient exposure to less effective therapies.

In Argentina, where regulatory frameworks are rapidly evolving, the implementation of can facilitate compliance with local requirements while upholding stringent study standards. Recent statistics indicate that such trial designs can yield a 20-30% reduction in overall research costs, a figure corroborated by industry analyses that highlight the financial advantages of these methodologies. Moreover, successful case studies in the region, particularly those employing , illustrate how have been effectively utilized to , providing valuable insights into treatment safety and efficacy.

As major regulatory agencies in Europe and the US continue to issue supportive guidelines for , the momentum for their adoption in Latin America is poised to increase. Engaging stakeholders and informing them about the benefits of these designs is crucial for their approval and effective application in . With bioaccess®’s expertise in managing (EFS), (FIH), Pilot Studies, Pivotal Studies, and Post-Market Clinical Follow-Up Studies (PMCF), Medtech companies can leverage these strategies to enhance study efficiency and reduce costs. By effectively employing , bioaccess® not only improves outcomes but also contributes to for Argentina, ensuring that resources are allocated judiciously throughout the process. As Philip Pallmann noted, “All authors read and approved the final manuscript,” underscoring the collaborative effort essential in clinical research. By fostering a deeper understanding of , bioaccess® can expedite medical innovations more swiftly.

Platform Trials

represent an innovative framework that facilitates the simultaneous evaluation of multiple interventions under a single master protocol. This methodology proves especially beneficial in oncology, where various therapies are frequently developed for the same indication. For instance, a platform experiment can assess different drugs targeting a specific cancer type, enabling swift comparisons of their efficacy and safety profiles.

In Argentina, the implementation of can significantly enhance collaboration among researchers and sponsors, streamlining and accelerating data collection. By leveraging a shared infrastructure, these studies can yield substantial cost reductions, positioning as a compelling choice for aiming to optimize their .

Notably, successful such as ENSEMBLE, RECOVERY, and ACTIV have illustrated the effectiveness of this approach in addressing urgent public health challenges. For example, the RECOVERY study facilitated the rapid evaluation of various therapies during the COVID-19 pandemic, underscoring the adaptive design’s versatility and responsiveness.

Furthermore, Brian Moore, VP at NICCA USA, Inc., noted, “The caliber of studies they have conducted for us has been outstanding,” highlighting the practical efficacy of platform tests. Additionally, with bioaccess®’s expertise in managing (EFS), , Pilot Studies, Pivotal Studies, and Post-Market Clinical Follow-Up Studies (PMCF), the complexities and successes related to can be navigated effectively.

This comprehensive medical study management approach not only enhances outcomes but also contributes to job creation, economic development, and healthcare improvement in the region. As the landscape of medical studies evolves in 2025, the advantages of platform experiments, supported by bioaccess®’s tailored services, will remain crucial in advancing medical technology and improving outcomes for individuals.

Basket Trials

represent a groundbreaking method in clinical research, allowing for the evaluation of a single investigational drug or treatment across various disease types that share a common genetic mutation or biomarker. This design is particularly advantageous in oncology, where can effectively address multiple cancers exhibiting similar molecular characteristics. For example, a basket study may assess a new in individuals with diverse tumor types, all of which display a specific mutation.

In Argentina, the healthcare system is progressively adapting to innovative treatment methods, with the adoption of , such as , serving as a strategic initiative to accelerate the advancement of . These studies not only enhance individual outcomes but also align with for the region, thereby optimizing resource distribution and managing expenses effectively. The success of basket experiments in Argentina is underscored by recent initiatives that have demonstrated their capacity to streamline the .

A notable example is the Basket of , which has successfully treated over 170 individuals by integrating a multidisciplinary to offer personalized therapy options. This research illustrates how can expand the range of available to individuals with specific genetic mutations, ultimately facilitating progress in . The results of the BoB study highlight the effectiveness of this approach, showcasing its ability to deliver customized therapies that enhance patient care.

Expert opinions further underscore the effectiveness of across various diseases, with oncologists stating that ‘the selection of method should be determined based on study priorities and the anticipated basketwise distribution of treatment effects.’ As the field of oncology continues to evolve, the current application of in research is gaining momentum, with ongoing investigations illustrating their significance in improving treatment effectiveness and care for patients. Moreover, statistics reveal that in recent studies, were reported at a rate of 0.4% in the molnupiravir group compared to 0.3% in the usual care group, emphasizing the importance of safety and efficacy in treatment assessments within .

Utilization of Real-World Evidence

Employing in research studies involves the collection of data from unconventional sources such as electronic health records, registries, and insurance claims. This methodology offers a comprehensive perspective on treatment performance in everyday medical environments. In Argentina, the strategic application of RWE enables researchers to identify groups of individuals who stand to gain the most from new therapies, thereby enhancing and facilitating . With bioaccess®’s extensive —including feasibility assessments, site selection, compliance evaluations, and project coordination—the integration of RWE becomes even more significant.

For instance, Lifebit’s federated technology provides from over 100 million individuals, thereby broadening the scope of data available for RWE in research studies. Moreover, RWE plays a crucial role in assisting by demonstrating the effectiveness and safety of treatments across various demographic groups. This not only accelerates approval processes but also enhances access to innovative treatments, ultimately contributing to . As stated, ‘an enhanced doesn’t solely aid sponsors and site personnel—it enables more individuals to engage in studies, which benefits all of us.’

Furthermore, the Lung Cancer Genetics Study Partnership with Lifebit exemplifies the successful application of RWE, aiming to deepen the understanding of lung cancer genetics and potentially leading to . The platform’s presence in over 100 nations additionally fosters collaboration among stakeholders in research studies, underscoring the global significance of RWE and the role of bioaccess® in promoting innovation and regulatory excellence within the Medtech industry.

Digital Health Technologies

, encompassing mobile health applications, wearable devices, and telemedicine, are revolutionizing research by enabling remote monitoring, , and enhancing engagement. For example, wearable devices continuously collect health data, providing researchers with . In Argentina, the successful integration of these technologies has yielded significant benefits, such as that streamline operations and reduce expenses. Notably, Phantom Neuro’s recent $19M funding to advance human-machine technology underscores the growing interest and financial backing for digital health innovations.

bioaccess® delivers comprehensive management services for research studies, which encompass feasibility assessments, site selection, , setup, import permits, , and reporting. These capabilities ensure that medical studies are conducted effectively and in compliance with local regulations, a critical factor for the successful integration of . Specifically, bioaccess’s experimental setup process involves meticulous planning and coordination with ethics committees and health ministries, while project management includes ongoing monitoring and reporting of study status and adverse events.

Nonetheless, the integration of these technologies presents challenges. Insights from Jones Day emphasize the necessity of addressing . Additionally, the involvement of in research studies introduces compliance challenges, as these companies may lack familiarity with research regulations. Effective integration requires diligent oversight to ensure adherence to regulatory standards. Furthermore, professional recommendations, such as those from Cave et al., highlight the potential of , enhancing the credibility of results in medical studies. By facilitating more convenient and accessible participation, digital health tools not only enhance but also contribute to more robust and reliable study outcomes. As the landscape of medical research evolves in 2025, the development of for Argentina will be pivotal, supported by and bioaccess’s extensive services, in improving overall research efficiency.

Feasibility Studies

that assess the practicality of proposed clinical trials. In Argentina, critically evaluate factors such as site capabilities, patient availability, and logistical considerations, all of which are vital given the country’s diverse healthcare landscape and varying patient demographics. By identifying potential challenges early, researchers can refine study designs to ensure they are both practical and efficient.

The importance of is underscored by findings from the Clinical Trials Journal, which reveal that studies incorporating comprehensive feasibility assessments achieve . This proactive approach not only increases the likelihood of success but also effectively manages costs, establishing as a fundamental component of the medical research process.

As exemplified by ReGelTec’s on HYDRAFIL™ for addressing chronic low back pain in Colombia, . This study, which involved eleven patients and was conducted remotely, illustrates how tailored approaches can lead to successful outcomes, highlighting the necessity for flexibility in medical investigations. Moreover, understanding the roles of regulatory affairs professionals and project managers is crucial for navigating the complexities of studies in Argentina. As the Medtech sector continues to evolve in 2025, the emphasis on for Argentina will remain vital for optimizing study frameworks and enhancing research outcomes. Bioaccess® offers personalized solutions, including , , and comprehensive study management services, ensuring that feasibility assessments are tailored to the specific contexts of Medtech companies, thereby reinforcing their commitment to advancing medical devices more swiftly.

Strategic Site Selection

Strategic location choice is vital for the success of , particularly regarding , where healthcare facilities can differ greatly. This procedure includes recognizing and assessing possible research locations according to essential factors like participant demographics, site capabilities, and . Effective site selection can dramatically enhance ; this is crucial given that up to 40% of research sites may experience , potentially compromising the validity of the study and leading to inconclusive results.

By utilizing real-world data and insights from previous studies, researchers can make informed decisions that not only improve study efficiency but also ensure high-quality data collection. This strategic approach minimizes costs associated with underperforming sites and accelerates the timeline for bringing new therapies to market. Moreover, expert insights emphasize that , which are thoroughly researched and context-specific strategies, are crucial for enhancing site selection. This ultimately affects and overall study results. The partnership between bioaccess™ and Caribbean Health Group, revealed on March 29, 2019, illustrates the significance of in establishing Barranquilla as a premier location for in Latin America. Backed by Colombia’s Minister of Health, this initiative seeks to improve the research environment, ensuring that locations are well-prepared to fulfill the requirements of contemporary studies.

Particular results from this partnership consist of a notable decrease in recruitment duration and , highlighting the efficacy of their strategic method. Furthermore, bioaccess®’s proficiency in overseeing different kinds of studies—including Early-Feasibility, , Pilot, Pivotal, and Post-Market Follow-Up Studies—underscores the necessity for thorough management services. By leveraging models like those suggested by Medidata, biopharmaceutical companies and CROs can make more and confidently select high-performing sites to meet enrollment timelines. This comprehensive method not only tackles the challenges of participant involvement but also emphasizes the significance of in achieving successful studies.

Partnerships with Local CROs

Collaborating with is essential for the success of . These organizations provide invaluable insights regarding the , cultural nuances, and demographics, which are critical for facilitating effective research operations. excel in navigating complex regulations, optimizing , and ensuring adherence to . This expertise not only streamlines testing procedures but also fosters , ultimately enhancing research outcomes.

Statistics indicate that 91.8% of studies in Argentina are funded by foreign manufacturers, underscoring the vital role of local collaborations for international Medtech companies. By leveraging the strengths of alongside bioaccess’s extensive management services—including , , and Post-Market Follow-Up Studies—companies can implement to improve operational efficiency and accelerate the advancement of innovative therapies within a competitive landscape. Furthermore, effective collaborations with have demonstrated that these partnerships can effectively address common challenges encountered in public healthcare environments, where bureaucracy often impedes research progress. In contrast, private for-profit hospitals, preferred by the majority of CROs, provide a more conducive environment for medical investigation activities, facilitating quicker and more effective execution of studies.

With over 20 years of experience in Medtech, bioaccess is well-equipped to navigate these complexities. Additionally, the research studies market in Argentina is projected to reach USD 506.1 million by 2030, highlighting the significance of in capitalizing on this growth. As Julio G. Martinez-Clark, CEO, observes, fosters an environment conducive to scientific advancement and collaborative global initiatives. This collaborative approach, bolstered by bioaccess’s expertise, is crucial for ensuring that reach the market swiftly and effectively. To maximize the benefits of these partnerships, it is advisable to engage with early in the study design process, allowing for the integration of their insights and the streamlining of operations.

Patient-Centric Trial Designs

prioritize the perspectives and preferences of participants throughout the research process. This methodology encompasses flexible scheduling, remote monitoring, and the integration of to boost . Notably, in 2022, the use of virtual elements in assessments surpassed levels seen in the years preceding the pandemic, underscoring the critical role of in enhancing patient-centered methods.

In Colombia, particularly in Barranquilla, where bioaccess™ and the Caribbean Health Group collaborate to establish the city as a premier location for , adopting a can significantly enhance . This approach has resulted in and 95% retention rates.

By actively engaging individuals in the study design process, researchers can develop investigations that align more closely with participant expectations, leading to improved outcomes and heightened satisfaction among contributors. Evidence indicates that studies incorporating participant feedback not only foster greater involvement but also yield more efficient and scientifically valid outcomes.

Furthermore, the establishment of is essential for equipping individuals for meaningful participation, ensuring their contributions are evidence-based and aligned with scientific objectives. As highlighted by Barger et al., communication through web conferences and emails has significantly improved study design and execution, emphasizing the necessity for .

Insights from the case study titled ‘Future Directions for ‘ suggest that creating is crucial for encouraging meaningful involvement in medical studies. This ultimately supports the objective of positioning Barranquilla as an appealing center for research in Latin America.

Regulatory Alignment Strategies

are essential for ensuring compliance with both local and international regulations in clinical research. In Argentina, where , it is imperative for researchers to stay updated on the latest guidelines and requirements related to . By implementing robust regulatory strategies, researchers can , minimize delays, and . As Gurudath Gurjal emphasizes, “Achieving regulatory alignment is vital for clinical study success.” This proactive approach not only enables more efficient operations but also cultivates trust among stakeholders, including regulatory agencies and individuals receiving care. Effective regulatory alignment is crucial for and improving patient outcomes in the Medtech sector.

bioaccess® offers extensive management services for studies that encompass:

• Feasibility assessments
• Site selection
• Compliance evaluations
• Setup
• Import permits
• Project oversight
• Reporting

In 2023, Argentina represented 0.4% of the global research market, with forecasts suggesting substantial expansion by 2030. As the fastest-growing regional market in Latin America, for researchers in the medical field to utilize . Remaining aware of regulatory compliance data, such as the recent rise in approval rates for clinical studies, is essential for successfully navigating this landscape. By leveraging , including the streamlined processes adopted by leading Medtech firms like bioaccess®, researchers can enhance and contribute to the advancement of medical technologies. This includes managing Early-Feasibility Studies, , Pilot Studies, Pivotal Studies, and Post-Market Clinical Follow-Up Studies (PMCF), which are critical for the success of innovative medical devices.

Conclusion

The evolution of clinical research in Argentina is profoundly shaped by innovative trial designs, including adaptive, platform, and basket trials. These methodologies provide exceptional flexibility and efficiency, enabling researchers to adjust protocols in real-time based on emerging data. By optimizing patient outcomes and minimizing costs, they present a compelling proposition for Medtech companies navigating the complexities of clinical trials in a rapidly evolving landscape.

The utilization of real-world evidence and digital health technologies significantly enhances the effectiveness of these trial designs. By harnessing data from electronic health records and patient registries, researchers can refine recruitment strategies, ensuring that trials accurately reflect real-world scenarios. The integration of digital tools also promotes patient engagement, making participation in clinical trials more accessible and aligned with patient needs.

Strategic partnerships with local CROs are vital in this context, as they offer essential insights into regulatory requirements and cultural nuances. Such collaborations not only streamline trial operations but also bolster the likelihood of successful outcomes. Furthermore, an emphasis on patient-centric designs ensures that trials resonate with participants, leading to improved recruitment and retention rates.

As the clinical trial market in Argentina continues its upward trajectory, embracing these innovative approaches will be crucial for advancing medical technologies and enhancing patient care. By prioritizing flexibility, collaboration, and patient engagement, the future of clinical research in Argentina appears promising, paving the way for breakthroughs that can transform healthcare delivery. The momentum gained from these methodologies will undoubtedly play a pivotal role in shaping the next generation of clinical trials, ensuring that new therapies reach patients more swiftly and effectively.

Frequently Asked Questions

What are adaptive study designs in clinical research?

Adaptive study designs are flexible methodologies that allow researchers to make real-time adjustments to study protocols based on emerging data, such as modifying sample sizes, treatment regimens, or endpoints as the study progresses.

How do adaptive study designs improve clinical research outcomes?

They enhance testing efficiency and reduce costs by reallocating participants to more effective treatment groups, minimizing unnecessary exposure to less effective therapies.

What are the cost benefits of adaptive study designs in Argentina?

Implementing cost-efficient trial designs can lead to a 20-30% reduction in overall research costs, helping researchers comply with local regulations while maintaining high study standards.

How do platform studies function in clinical research?

Platform studies allow for the simultaneous evaluation of multiple interventions under a single master protocol, making them particularly useful in oncology where several therapies may target the same indication.

What advantages do platform studies offer in Argentina?

They enhance collaboration among researchers and sponsors, streamline patient recruitment, and accelerate data collection, resulting in significant cost reductions for Medtech firms.

Can you provide examples of successful platform studies?

Successful platform studies include ENSEMBLE, RECOVERY, and ACTIV, which have effectively addressed public health challenges, such as the rapid evaluation of therapies during the COVID-19 pandemic.

What are basket studies in clinical research?

Basket studies evaluate a single investigational drug across various disease types that share a common genetic mutation or biomarker, particularly beneficial in oncology for targeted therapies.

How are basket studies advancing personalized medicine in Argentina?

They optimize resource distribution and manage expenses effectively, aligning with the region’s strategic initiatives to accelerate personalized treatment options.

What is the significance of the Basket of Baskets (BoB) study?

The BoB study has successfully treated over 170 individuals by utilizing a multidisciplinary approach to offer personalized therapy options, demonstrating the effectiveness of basket studies in enhancing patient care.

What do experts say about the effectiveness of basket studies?

Experts suggest that the choice of study method should be based on priorities and the expected distribution of treatment effects, underscoring the importance of tailored approaches in clinical research.

List of Sources

1. Adaptive Trial Designs
   • bmcmedicine.biomedcentral.com (https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-018-1017-7)
   • pmc.ncbi.nlm.nih.gov (https://pmc.ncbi.nlm.nih.gov/articles/PMC10772057)
   • alimentiv.com (https://alimentiv.com/different-types-of-clinical-trial-designs)
2. Platform Trials
   • grandviewresearch.com (https://grandviewresearch.com/market-trends/platform-trials-market-trend-analysis)
   • 35.183.20.180 (https://35.183.20.180/case_studies/trials-supporting-approvals-for-dlbcl)
3. Basket Trials
   • researchgate.net (https://researchgate.net/publication/386497688_Master_protocols_in_Low-and-Middle_income_countries_A_review_of_current_use_limitations_and_opportunities_for_precision_medicine)
   • trialsjournal.biomedcentral.com (https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-019-3664-1)
   • cancercoreeurope.eu (https://cancercoreeurope.eu/bob-pioneering-basket-trials-solid-tumors)
4. Utilization of Real-World Evidence
   • lifebit.ai (https://lifebit.ai/blog/benefits-real-world-data-clinical-research-trials)
   • onestudyteam.com (https://onestudyteam.com/resources-ebooks-clinical-trial-enrollment)
   • graduate.northeastern.edu (https://graduate.northeastern.edu/knowledge-hub/real-world-evidence-impact-on-healthcare)
5. Digital Health Technologies
   • mobihealthnews.com (https://mobihealthnews.com/content/77-2015s-most-interesting-digital-health-quotes)
   • jonesday.com (https://jonesday.com/en/insights/2020/06/jones-day-presents-the-impact-of-digital-health-on-research-and-clinical-trials)
   • Using digital technologies in clinical trials: current and future applications – PMC (https://pmc.ncbi.nlm.nih.gov/articles/PMC8734581)
6. Feasibility Studies
   • gcp-service.com (https://gcp-service.com/the-impact-of-feasibility-on-clinical-trial-outcomes)
   • Conducting Feasibilities in Clinical Trials: An Investment to Ensure a Good Study – PMC (https://pmc.ncbi.nlm.nih.gov/articles/PMC3146075)
   • clinicalresearchnewsonline.com (https://clinicalresearchnewsonline.com/news/2025/04/11/feasibility-the-art-of-being-less-wrong-faster)
   • fastercapital.com (https://fastercapital.com/topics/understanding-the-importance-of-feasibility-studies-in-cost-estimation.html)
7. Strategic Site Selection
   • 5 common clinical trial patient recruitment challenges and solutions (https://antidote.me/blog/5-common-clinical-trial-patient-recruitment-challenges-and-solutions)
   • biobostonconsulting.com (https://biobostonconsulting.com/top-5-alarming-statistics-on-clinical-trial-site-selection-bioboston-consulting)
   • The Top 200 Strategy & Strategic Planning Business Quotes (https://praxie.com/top-business-strategy-strategic-planning-quotes)
   • medidata.com (https://medidata.com/en/life-science-resources/medidata-blog/clinical-trial-planning-predictive-site-selection-trial-rescue-predictive-analytics)
8. Partnerships with Local CROs
   • Will Argentina Be The Next Medtech Clinical Trial Destination In Latin America? (https://meddeviceonline.com/doc/will-argentina-be-the-next-medtech-clinical-trial-destination-in-latin-america-0001)
   • cphi-online.com (https://cphi-online.com/argentina-proving-popular-with-cros-news031474.html)
   • grandviewresearch.com (https://grandviewresearch.com/horizon/outlook/clinical-trials-market/argentina)
9. Patient-Centric Trial Designs
   • pharmaceutical-technology.com (https://pharmaceutical-technology.com/sponsored/why-patient-centricity-is-the-answer-to-the-clinical-trial-enrolment-gap)
   • pmc.ncbi.nlm.nih.gov (https://pmc.ncbi.nlm.nih.gov/articles/PMC10527717)
10. Regulatory Alignment Strategies

• icmra.info (https://icmra.info/drupal/en/news/30April2020)
• Will Argentina Be The Next Medtech Clinical Trial Destination In Latin America? (https://meddeviceonline.com/doc/will-argentina-be-the-next-medtech-clinical-trial-destination-in-latin-america-0001)
• grandviewresearch.com (https://grandviewresearch.com/horizon/outlook/clinical-trials-market/argentina)
• linkedin.com (https://linkedin.com/pulse/navigating-regulatory-alignment-ensure-timely-trial-approval-gurjal-nmvfc)

Introduction

Clinical research plays a crucial role in advancing medical knowledge and developing groundbreaking treatments. In this article, we will explore the achievements and contributions of several leading clinical research companies. From successfully conducting clinical trials in various therapeutic areas to facilitating international collaborations and navigating complex trial processes, these companies have made significant strides in improving patient care.

We will delve into their accomplishments, methodologies, and the impact they have had on healthcare innovation. Join us as we explore the world of clinical research and the transformative role it plays in shaping the future of medicine.

Company A: Description and Achievements

Company A is a leading that has made significant contributions to advancing . With a team of skilled researchers and state-of-the-art facilities, Company A has successfully conducted numerous across various therapeutic areas. Their dedication to research excellence and commitment to have earned them a reputation as a trusted partner in the industry.

Company A’s achievements include the successful development of several and the publication of numerous .

Company B: Description and Achievements

Company B is distinguished within the landscape, earning accolades for facilitating vital studies that propel scientific innovation. Their team, proficient and seasoned, wields advanced methodologies to administer with commendable exactitude and operational efficiency. Authenticated by a solid history, Company B’s endeavors in various therapeutic areas have not only culminated in intricate studies that meet completion but have also shed light on invaluable medical revelations.

These achievements contribute substantially to the advent of novel treatments, an effort celebrated by industry-wide recognition and several esteemed awards. Reflective of this expertise, consider the complexities encountered when a patient must —a testament to the intricate landscape Company B adeptly navigates. By optimizing each decisive link in the complex chain of , the organization mirrors the success of pioneers like CMIC Group in Japan, who revolutionized the CRO industry and now offer end-to-end solutions.

This comprehensive approach is vital, ensuring that made early on can withstand the rigor of time and significantly impact study outcomes. Company B’s prestigious position corroborates their capacity to foresee a project’s trajectory and meticulously tailor robust, that transcend geographical and logistical challenges.

Company C: Description and Achievements

At the forefront of medicinal discovery, Company C exemplifies the high caliber of that are pivotal to developing . Their has spearheaded with academic powerhouses and leading pharmaceutical firms, facilitating monumental strides in healthcare. One stark example involves a patient with a rare disease in rural Pennsylvania grappling with the possibility of joining a clinical trial abroad.

Despite the complexities of international travel and language barriers, it is through the efforts of a clinical trial company like Company C that opportunities for lifesaving treatments are made accessible. The Chronic Pain Network’s model of into research processes underscores the importance of these collaborations, where the synergy of patient experience and clinical expertise fosters . Statistics reinforce the dynamism of this industry; forward-looking statements reflect a tapestry of operations and outcomes hinged on the progress of .

Company C navigates a future replete with possibilities – from the launch of novel pharmaceuticals to the expansion of markets for new therapies. Mitigated by nuanced risks and uncertainties, the company’s trajectory is a testament to its unwavering commitment to cultivating scientific knowledge and enhancing patient well-being.

Company D: Description and Achievements

Fulfilling a vital role in the ever-evolving landscape of healthcare, Company D stands out as a with over two decades of dedicated service. Their targeted expertise in navigating the complexities of has cemented their reputation as a bastion of innovation and . A pivotal element of their approach involves an intense focus on .

This methodology allows for a dynamic reevaluation of trial strategies to optimize outcomes, an aspect echoed by industry experts who acknowledge that a staggering 80% of , if better scrutinized, could enhance results considerably. Company D’s methodical attention to detail ensures that each phase of a study is strategically reinforced like the links of a chain, adapted precisely to the timeframes and objectives central to the research at hand. This commitment has not only advanced the development of but has also deepened the broader understanding of complex disease mechanisms.

Through their relentless pursuit of excellence and adherence to ethical standards, Company D has garnered esteem within the scientific community, serving as a trusted beacon of high-quality research and development.

Company E: Description and Achievements

Company E stands at the forefront of clinical research, distinguished by their unwavering commitment to . With a spectrum of research studies that traverse numerous therapeutic domains, Company E’s track record is highlighted by the successful execution of crucial . These pivotal trials are fundamental to the endorsement of new treatments that elevate patient care standards.

Their resolve for innovation is apparent in their , aiming at the introduction of into the market. Achieving such milestones is not without challenges; the future operations and outcome of involve complex layers of anticipation and informed predictions. Forward-looking statements released by Company E reflect these endeavors, encompassing potential future events and outcomes.

These expectations, informed by historical data and projected trends, remain subject to a gamut of risks and uncertainties, including trial enrollment timelines, successes of ongoing research, , and intellectual property acquisition and protection. Moreover, the trajectory of market trends, market receptivity to novel products, and navigating the regulatory landscape are critical facets that influence Company E’s strategic direction.

Company F: Description and Achievements

Renowned for driving innovation in the medical field, Company F is a adept in the orchestration of early-phase . Their pioneering work centers around developing state-of-the-art trial designs and methodologies that have contributed substantially to . Marking their influence, Company F has steered the discovery of groundbreaking biomarkers and ratified pioneering diagnostic tools.

With a core philosophy rooted in perpetual development, they channel considerable resources into the enhancement of their research team, ensuring perpetual progression at the cutting-edge of clinical science.

As an illustration of their impact on individual lives, envision a patient in rural Pennsylvania, plagued by an ultra-rare disease with no sanctioned treatments, who receives an offer to join a clinical trial half a world away in Turkey. The confluence of hope and logistical challenges—securing visas, navigating foreign paperwork, coordinating international travel—highlights the critical complexity present for participants.

This anecdote underscores the necessity for comprehensive, . As an advisory professional from Treehill Partners articulated, reflecting on decades of transaction advisory, a significant number of companies conducting Phase I-III trials confessed that, in hindsight, decisions could have been more strategically iterated if guided by CROs with a more investment in the process.

In consonance with this viewpoint, CMIC Group, a trailblazer in Japan’s CRO business, epitomizes the evolution within the industry by offering expansive, that address each phase of pharmaceutical product development. By tailoring their services, CMIC exemplifies how a CRO’s dedication can pivot on furnishing pharmaceutical firms, medical device manufacturers, and research institutions with precision resources that propel the journey of medical products from conception to fruition.

Company G: Description and Achievements

Company G is an esteemed company known for its expertise in the field. They have a broad range of capabilities, including , , and . Company G’s achievements include the successful execution of large-scale and the development of robust systems.

They have been instrumental in in areas such as oncology, neurology, and infectious diseases.

Company H: Description and Achievements

Company H stands at the forefront of clinical research, manifesting its profound impact on healthcare with the delivery of groundbreaking . This distinguished entity is composed of a versatile team of across diverse therapeutic disciplines, each contributing their expertise to the collective pursuit of scientific innovation. Central to Company H’s ethos is a resolute commitment to and the adherence to the highest standards, safeguarding the integrity and effectiveness of their research.

Their most laudable achievements hinge on the orchestration of that have heralded the advent of novel treatments and notably enhanced the quality of patient care. Drawing inspiration from industry pioneers like Pfizer, Company H echoes the sentiment that every endeavor aims to yield ”. This dedication resonates deeply within their culture, spurring continual progress and echoing Charles Pfizer’s original vision of creating a substantive impact that extends to patients and the broader society.

In emulate of CMIC Group’s trailblazing path in Japan, Company H also prides itself on being a comprehensive solutions provider, positioned to meet the evolving demands of the . Their multidisciplinary approach not only propels the approval of new therapies but also transforms the lives of patients, their families, and caregivers by embracing a holistic perspective on health and wellbeing.

Company I: Description and Achievements

With a legacy of over three decades, Company I has emerged as a global frontrunner in clinical research, offering an array of services that cover the full spectrum of the . Their pioneering work began as Japan’s original and has expanded beyond its borders, demonstrating a capacity to manage and execute on an international scale. At the heart of Company I’s success is a holistic approach that includes expert proficiency in , innovative study design, and meticulous data analysis.

Company I garners respect for not only sustaining high-quality data standards but also for its role in informing medical decision-making on a vast scale. They leverage robust partnerships with academic entities and influential thought leaders, ensuring that their research offers tangible, real-world benefits. This ethos is encapsulated by the organization’s commitment to providing , which has made it a preferred partner for a diverse client base including pharmaceutical companies, medical device manufacturers, academicians, and bio-ventures.

Company J: Description and Achievements

Company J stands as a beacon in the realm of , with over three decades of pioneering history in therapeutic research. Originating as Japan’s first-ever (CRO), this seasoned innovator now offers end-to-end solutions spanning the full pharmaceutical value chain. Renowned for crafting such as cardiology, endocrinology, and dermatology, Company J has propelled from concept to marketplace.

Their commitment is best encapsulated in their ethos of striving for ‘,’ a sentiment echoed by CMIC Group—a leader in Japan’s CRO landscape—to mirror the and societal well-being. Far exceeding the role of a mere intermediary, Company J’s partnerships are a testament to their revered capability to metamorphose patient care not only through scientific ingenuity but also by enriching the lives of patients, their families, and communities.

Call to Action

Since its inception as a bold venture under Google X in 2015, Verily has dramatically changed the landscape of . Boasting a suite of products that have rocked the industry, Verily exemplifies companies at the vanguard of . Their Viewpoint platform transforms , enhancing evidence generation and streamlining participant recruitment, which, at the core of its latest Workbench tool, offers robust data insights.

The company’s prowess is further demonstrated by Onduo, a revolutionary virtual management platform assisting individuals with chronic conditions such as diabetes and hypertension, to navigate their health more effectively. Verily’s approach is emblematic of a dynamic healthcare industry shift towards precision health, with a mission “to bring the promise of precision health to everyone, every day.” Distancing itself from generic treatments designed for the ‘average patient,’ Verily, through the use of data science and advanced analytics, endeavors to tailor health care to suit individuals’ unique needs.

Verily’s success underscores the significant role of research companies in propelling and patient care. The philosophy that underpins their mission resonates with their commitment to breakthroughs and transformative change in patients’ lives. These are not mere improvements but radical shifts that consider the patient’s entire ecosystem, including family and social circles.

The words of a Tree hill advisor reflect this transformative spirit: “So, if we think of it from a chain perspective, like links in a chain, each of the links in the chain is optimized for the time frame that is relevant for the company.” Collaborating with trailblazers like Verily ensures of the highest quality, leading to enhanced patient outcomes and a significant leap forward in medical science.

Conclusion

In conclusion, the highlighted clinical research companies, including Company A, Company B, Company C, Company D, Company E, Company F, Company G, Company H, Company I, and Company J, have made significant contributions to advancing medical knowledge and improving patient care. They have conducted successful clinical trials and developed groundbreaking treatments in various therapeutic areas. These companies have shown dedication to research excellence, patient safety, and strategic trial management.

Their collaborations with academic institutions and pharmaceutical firms have facilitated important advancements in healthcare. The impact of their work extends beyond new treatment development; they have also made significant strides in understanding disease mechanisms and discovering innovative biomarkers and diagnostic tools. These companies are shaping the future of medicine by embracing patient-centered approaches, optimizing trial strategies, and leveraging data-driven decision-making.

By collaborating with industry trailblazers like Verily, they continue to drive innovation and improve patient outcomes. Overall, their commitment to research excellence and patient well-being positions them as leaders in the field, making a lasting impact on the healthcare industry.

Learn how bioaccess™ can help your company drive innovation and improve patient outcomes through strategic collaboration.

Frequently Asked Questions

What do Company A’s achievements in clinical research include?

Company A’s achievements include the successful development of several groundbreaking treatments and the publication of numerous influential research papers.

How is Company B recognized in the clinical research industry?

Company B is known for facilitating vital studies that advance scientific innovation and has earned industry-wide recognition and several prestigious awards for its contributions.

What is a notable aspect of Company C’s approach to clinical trials?

Company C adopts a patient-centered approach, collaborating with academic institutions and pharmaceutical companies to facilitate important healthcare advancements.

What specialized area of clinical trials is Company D known for?

Company D is renowned for its expertise in phase III clinical trials and its data-driven decision-making approach to optimize trial outcomes.

What distinguishes Company E in the field of clinical research?

Company E is recognized for executing crucial clinical trials across various therapeutic domains and for its strategic collaborations aimed at introducing groundbreaking treatments.

How does Company F contribute to the advancement of medical science?

Company F is instrumental in developing innovative trial designs and methodologies, as well as discovering biomarkers and diagnostic tools through early-phase clinical trials.

What capabilities does Company G have in clinical research?

Company G has a broad range of capabilities, including clinical operations, data management, and biostatistics, and has conducted successful large-scale multinational trials.

What ethos drives Company H’s clinical research efforts?

Company H is driven by a commitment to patient safety and adherence to the highest research standards, focusing on clinical trials that lead to novel treatments and enhanced patient care.

What is Company I’s role in the global clinical research arena?

Company I is a global leader offering a full spectrum of pharmaceutical development services, known for its regulatory expertise, innovative study design, and data analysis.

How does Company J impact therapeutic research and patient care?

Company J, as Japan’s first CRO, offers personalized strategies in therapeutic research, contributing to the development of therapies that change patients’ lives.

What is Verily’s contribution to healthcare innovation?

Verily revolutionizes healthcare with products like Viewpoint and Onduo, focusing on precision health tailored to individual needs and transforming the way clinical studies and chronic conditions are managed.

What is Verily’s mission?

Verily’s mission is “to bring the promise of precision health to everyone, every day,” aiming to create transformations in healthcare that are personalized and consider the patient’s entire ecosystem.

What is the significance of research companies like Verily in the medical field?

Research companies like Verily play a crucial role in enhancing patient outcomes, leading to advances in medical science, and offering high-quality clinical trials.

List of Sources

2. Company B: Description and Achievements
   • medhealthoutlook.com (https://medhealthoutlook.com/three-best-practices-to-combat-clinical-trial-pain-points-scott-gray-ceo-of-clincierge/)
   • biospace.com (https://www.biospace.com/article/treehill-partners-ali-pashazadeh-on-how-to-improve-clinical-trial-design/?utm_source=dlvr.it&utm_medium=twitter)
   • en.cmicgroup.com (https://en.cmicgroup.com)
   • globaldata.com (https://www.globaldata.com:443/store/report/innovation-and-patenting-activity-of-maravai-lifesciences-holdings-inc-innovation-and-trend-analysis/)
3. Company C: Description and Achievements
   • medhealthoutlook.com (https://medhealthoutlook.com/three-best-practices-to-combat-clinical-trial-pain-points-scott-gray-ceo-of-clincierge/)
   • researchinvolvement.biomedcentral.com (https://researchinvolvement.biomedcentral.com/counter/pdf/10.1186/s40900-023-00491-w)
   • ir.regenxbio.com (https://ir.regenxbio.com/news-releases/news-release-details/regenxbio-announces-new-positive-data-affinity-duchenner-trial)
4. Company D: Description and Achievements
   • biospace.com (https://www.biospace.com/article/treehill-partners-ali-pashazadeh-on-how-to-improve-clinical-trial-design/?utm_source=dlvr.it&utm_medium=twitter)
5. Company E: Description and Achievements
   • ir.regenxbio.com (https://ir.regenxbio.com/news-releases/news-release-details/regenxbio-announces-new-positive-data-affinity-duchenner-trial)
6. Company F: Description and Achievements
   • medhealthoutlook.com (https://medhealthoutlook.com/three-best-practices-to-combat-clinical-trial-pain-points-scott-gray-ceo-of-clincierge/)
   • biospace.com (https://www.biospace.com/article/treehill-partners-ali-pashazadeh-on-how-to-improve-clinical-trial-design/?utm_source=dlvr.it&utm_medium=twitter)
   • en.cmicgroup.com (https://en.cmicgroup.com)
   • medhealthoutlook.com (https://medhealthoutlook.com/three-best-practices-to-combat-clinical-trial-pain-points-scott-gray-ceo-of-clincierge/)
7. Company H: Description and Achievements
   • pfizer.com (https://www.pfizer.com/about/purpose)
   • en.cmicgroup.com (https://en.cmicgroup.com)
8. Company I: Description and Achievements
   • en.cmicgroup.com (https://en.cmicgroup.com)
9. Company J: Description and Achievements

• pfizer.com (https://www.pfizer.com/about/purpose)
• en.cmicgroup.com (https://en.cmicgroup.com)
• venngage.com (https://venngage.com/blog/fishbone-diagram-examples/)

11. Call to Action

• forbes.com (https://www.forbes.com/sites/saibala/2023/10/16/verily-is-boldly-innovating-the-future-of-healthcare/)
• pfizer.com (https://www.pfizer.com/about/purpose)
• biospace.com (https://www.biospace.com/article/treehill-partners-ali-pashazadeh-on-how-to-improve-clinical-trial-design/?utm_source=dlvr.it&utm_medium=twitter)

Introduction

Mastering clinical trial management in Argentina is essential for researchers aiming to navigate its complex regulatory landscape effectively. This unique environment demands not only a nuanced understanding of regulations but also the implementation of effective project management strategies. By exploring best practices, researchers can uncover invaluable insights that streamline processes and significantly enhance the success rates of their studies. Yet, challenges such as recruitment hurdles and compliance complexities persist.

So, how can clinical trial teams adeptly maneuver through this intricate landscape to achieve their objectives?

Understand Regulatory Frameworks for Clinical Trials in Argentina

Navigating the regulatory environment in Argentina is crucial for the success of research studies. The National Administration of Drugs, Food and Medical Technology (ANMAT) has implemented significant reforms, establishing a legally binding maximum approval timeline of 62 days for clinical studies. Understanding ANMAT regulations, especially the Good Clinical Practice (GCP) guidelines, is vital. These guidelines mandate the preparation of detailed research protocols, meticulous record-keeping, and strict adherence to ethical standards.

Engaging with regional regulatory specialists can provide essential insights, facilitating smoother interactions with ANMAT. This approach not only decreases delays but also enhances study efficiency. Recent updates indicate that the average timeline for medical research approvals in Argentina has improved, showcasing the positive impact of these regulatory changes on the research landscape.

Furthermore, bioaccess’s Global Trial Accelerators™ offer critical insights into regulatory updates and market entry strategies. This includes addressing cultural sensitivity in study design, which is essential for effectively engaging the Argentine population. Ensuring that research resonates with local customs and health practices is key to successful outcomes.

Implement Effective Project Management Strategies

Implementing strong project management strategies is essential for the success of research studies. A clear project plan that defines objectives, timelines, and responsibilities is the foundation of effective management. As Winston Churchill wisely stated, “Let our advance worrying become advance thinking and planning,” underscoring the necessity of structured planning in achieving research goals.

Utilizing effective project management tools significantly enhances tracking progress and facilitates communication among team members. Miscommunication is a common issue in research, as highlighted by George Bernard Shaw. Regularly reviewing project milestones allows for timely adjustments to address emerging challenges. It’s alarming that nearly 90% of drug candidates fail in clinical development due to inefficiencies, making proactive management crucial.

Effective risk management is equally vital. Identifying potential risks early and developing contingency plans can mitigate issues before they escalate. With 70% of rescue engagements stemming from low enrollment, proactive planning becomes essential. Cultivating an environment of openness and teamwork can improve team performance, ensuring that the project stays on schedule and achieves its goals.

The financial consequences of inadequate project performance are substantial. An estimated $30 million is squandered per attempt due to inefficiencies, highlighting the essential need for effective project management. By embracing these strategies, research teams can enhance their chances of success and drive impactful outcomes.

Recruit and Retain Qualified Research Personnel

Recruiting and retaining qualified research personnel is essential for the success of clinical studies. Clearly outlining the roles and responsibilities required for your assessment is the first step. Actively seek candidates with relevant experience through local networks and professional organizations. Once you have the right team in place, invest in their training and development to enhance their skills, ensuring they are well-versed in legal procedures and compliance requirements.

Creating a positive work environment is crucial. Foster collaboration and recognize achievements to keep morale high. Implement retention strategies such as competitive compensation, career advancement opportunities, and regular feedback to maintain motivation and engagement. Research indicates that 80% of medical studies fail to meet initial enrollment expectations, highlighting the critical importance of effective recruitment methods. Additionally, 19% of studies are closed due to insufficient enrollment, underscoring the need for proactive measures.

As Tiffany Ashton, Director of Operations and Clinical Trial Manager, aptly states, “Recruitment and retention are a team effort-and when we work together toward a common goal, we are more likely to achieve success.” By focusing on these strategies, you can enhance your team’s capabilities and contribute significantly to the success of your research studies.

Leverage Local Patient Populations for Faster Recruitment

Engaging local patient populations is essential for enhancing recruitment in clinical studies. By collaborating with community leaders and healthcare providers, awareness about the study and its potential benefits can significantly increase. Informational sessions allow potential participants to grasp the process and voice any concerns, fostering trust and transparency.

Targeted marketing strategies, such as social media outreach and community advertising, are crucial for reaching diverse patient populations. Research shows that nearly half of potential participants discover clinical studies through media and the internet, underscoring the necessity for a robust online presence.

Building trust within the community is vital; involving local physicians as advocates can bolster credibility and encourage participation. Effective community engagement strategies not only accelerate recruitment timelines but also enhance the overall quality of study data. By cultivating strong relationships with local communities, studies can achieve better enrollment outcomes and ultimately support more successful research initiatives.

Furthermore, with bioaccess’s approach, clinical studies can realize $25K savings per patient, achieve 50% faster enrollment through pre-qualified networks, and enjoy a 30% reduction in overall study costs. Given that over 60% of sites fail to meet their original patient enrollment goals and nearly 80% of patient recruitment timelines are unmet, these strategies are increasingly critical.

Conclusion

Mastering clinical trial management in Argentina is essential for advancing medical research and improving patient care. It demands a thorough understanding of the regulatory landscape, effective project management strategies, and a commitment to recruiting and retaining qualified personnel. By integrating these critical elements, research teams can adeptly navigate the complexities of clinical studies, ensuring compliance and operational efficiency.

Key insights throughout this discussion underscore the necessity of familiarizing oneself with ANMAT regulations, implementing structured project management practices, and leveraging local patient populations for recruitment. Engaging regulatory specialists, utilizing effective management tools, and fostering a positive work environment are pivotal steps that collectively enhance the likelihood of successful outcomes in clinical trials.

In summary, the path to successful clinical trial management in Argentina transcends mere regulatory adherence; it involves building robust teams and actively engaging with local communities. By adopting these best practices, research teams can significantly bolster their chances of success, ultimately contributing to advancements in medical science and patient care. Embracing these strategies today can pave the way for a more efficient and impactful clinical research landscape in Argentina.

Frequently Asked Questions

What is the role of ANMAT in clinical trials in Argentina?

The National Administration of Drugs, Food and Medical Technology (ANMAT) is responsible for regulating clinical trials in Argentina, ensuring compliance with established guidelines and standards.

What is the maximum approval timeline for clinical studies set by ANMAT?

ANMAT has established a legally binding maximum approval timeline of 62 days for clinical studies.

Why is understanding Good Clinical Practice (GCP) guidelines important?

Understanding GCP guidelines is vital as they mandate the preparation of detailed research protocols, meticulous record-keeping, and strict adherence to ethical standards in clinical trials.

How can engaging with regional regulatory specialists benefit clinical trials?

Engaging with regional regulatory specialists can provide essential insights, facilitate smoother interactions with ANMAT, decrease delays, and enhance study efficiency.

What recent trends have been observed in the approval timelines for medical research in Argentina?

Recent updates indicate that the average timeline for medical research approvals in Argentina has improved, reflecting the positive impact of regulatory changes on the research landscape.

What resources does bioaccess provide for navigating regulatory frameworks?

Bioaccess’s Global Trial Accelerators™ offer critical insights into regulatory updates and market entry strategies, aiding in the navigation of the regulatory environment for clinical trials.

Why is cultural sensitivity important in study design for clinical trials in Argentina?

Cultural sensitivity is essential for effectively engaging the Argentine population, ensuring that research resonates with local customs and health practices, which is key to successful outcomes.

List of Sources

1. Understand Regulatory Frameworks for Clinical Trials in Argentina
   • linkedin.com (https://linkedin.com/posts/intrials-clinical-research_intrials-activity-7386780565036765185-0lEy)
   • Challenges in Designing Trials for Argentina: Key Considerations | bioaccess® (https://bioaccessla.com/blog/challenges-in-designing-trials-for-argentina-key-considerations)
   • executiveforecast.com (https://executiveforecast.com/conversation/argentinas-clinical-trial-renaissance-interview-with-mariel-peitiado—president-camara-argentina-de-organizaciones-de-investigacion-clinica-caoic-argentina)
   • linkedin.com (https://linkedin.com/pulse/argentina-entering-new-regulatory-era-anmat-already-schiavone-md-n5izf)
2. Implement Effective Project Management Strategies
   • xceneresearch.com (https://xceneresearch.com/project-management-in-clinical-research)
   • 35 Best Project Management Quotes (https://projectmanager.com/blog/10-best-project-management-quotes)
   • 72 Project Management Quotes to Inspire Your Next Project (https://toggl.com/blog/project-management-quotes)
   • The 62 Most Inspiring Project Management Quotes (https://inloox.com/company/blog/articles/the-62-most-inspiring-project-management-quotes)
3. Recruit and Retain Qualified Research Personnel
   • 2025 Trends In Patient Recruitment: From Disruption To Precision (https://clinicalleader.com/doc/trends-in-patient-recruitment-from-disruption-to-precision-0001)
   • 25+ useful clinical trial recruitment statistics for better results (https://antidote.me/blog/25-useful-clinical-trial-recruitment-statistics-for-better-results)
   • A Primer on the Importance of Recruitment and Retention in Clinical Trials – ACRP (https://acrpnet.org/2023/04/18/a-primer-on-the-importance-of-recruitment-and-retention-in-clinical-trials)
   • Recruitment and retention of participants in randomised controlled trials: a review of trials funded and published by the United Kingdom Health Technology Assessment Programme (https://bmjopen.bmj.com/content/7/3/e015276)
   • autocruitment.com (https://autocruitment.com/blogs/current-challenges-in-clinical-trial-patient-recruitment-and-enrollment)
4. Leverage Local Patient Populations for Faster Recruitment
   • Enrollment Performance: Weighing the “Facts” | Applied Clinical Trials Online (https://appliedclinicaltrialsonline.com/view/enrollment-performance-weighing-facts)
   • veristat.com (https://veristat.com/patient-recruitment-for-clinical-trials)
   • 25+ useful clinical trial recruitment statistics for better results (https://antidote.me/blog/25-useful-clinical-trial-recruitment-statistics-for-better-results)
   • Evaluation of factors associated with recruitment rates in early phase clinical trials based on the European Clinical Trials Register data (https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.13659)
   • 2025 Trends In Patient Recruitment: From Disruption To Precision (https://clinicalleader.com/doc/trends-in-patient-recruitment-from-disruption-to-precision-0001)